2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 959

A Novel Image Analysis Program, “CytoSkaler”, Demonstrates That Anti-Vimentin Antibody Affinity Maturation in Lupus Tubulointerstitial Nephritis Also Results in More Selective Antigen Targeting
Abstract Number: 960

Autoantibodies in Rheumatoid Arthritis Target Citrulline-Containing and Native Epitopes from Conformationally Disordered Regions of Proteins
Abstract Number: 961

Microenvironment in Systemic Sclerosis Provides a Protective Niche for Tissue-resident B Cells During B Cell Depletion Therapy with Anti-CD20 Antibody
Abstract Number: 962

The Presence of Circulating CD19+CD21lo cells Predicts the Presence of Interstitial Lung Disease in Patients with Systemic Sclerosis
Abstract Number: 963

Alterations of Memory and Naive B Cell Subsets Associate with Reduced IFNα and TNFRII in ANA+ Healthy Individuals
Abstract Number: 964

Identifying Jo-1-Specific B Cells in the Primary Immune Repertoire in Idiopathic Inflammatory Myopathies
Abstract Number: 965

Discovery of DWP212525, a Potent JAK3 and BTK Dual Target Inhibitor for the Treatment of Autoimmune Diseases
Abstract Number: 966

Minimal Residual Autoimmunity After Rituximab in ANCA-associated Vasculitis Patients
Abstract Number: 967

Bruton’s Tyrosine Kinase (BTK) Pathway Is Active in Synovium at Various Stages of Rheumatoid Arthritis Disease Progression
Abstract Number: 968

Circulating PR3-Specific B Cells in Patients with Active ANCA-Associated Vasculitis
Abstract Number: 969

ß-adrenergic Receptor Activation: A Way to Enhance CD4 T Cell Suppression by Improving Regulatory B Cell Function
Abstract Number: 970

New-onset ANCA-associated Vasculitis Is Associated with Significant Phenotypic B Cell Dysfunction
Abstract Number: 971

B Cell ROCK1 Promotes Germinal Center Responses and Is Required for Optimal Humoral Immunity
Abstract Number: 972

Disease Severity Is Linked to an Increase in Autoantibody Diversity in IgG4-related Disease
Abstract Number: 973

Serum IgG4 Concentrations Differ According to Race and Sex

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].